{"id":7490,"date":"2025-07-07T15:42:32","date_gmt":"2025-07-07T15:42:32","guid":{"rendered":"https:\/\/stoxpo.com\/?p=7490"},"modified":"2025-07-07T15:42:33","modified_gmt":"2025-07-07T15:42:33","slug":"regencell-biosciences-stock-whipsaws-again-amid-17000-surge-in-2025","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/07\/07\/regencell-biosciences-stock-whipsaws-again-amid-17000-surge-in-2025\/","title":{"rendered":"Regencell Bioscience\u2019s Stock Whipsaws Again Amid 17,000% Surge in 2025"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Following a 38-to-1 stock split and explosive rally, the biotech firm&#8217;s volatile trading persists despite a multi-year loss streak<\/h4>\n\n\n\n<p>Regencell Bioscience Holdings (RGC) continued its dramatic stock market saga on Monday, with shares swinging wildly throughout the trading session. After opening higher, the stock quickly turned lower, oscillating between gains and losses before settling down around 4%.<\/p>\n\n\n\n<p>The Hong Kong-based biotech firm\u2014focused on using traditional Chinese medicine to treat Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD)\u2014has captured investor attention in recent weeks. A key catalyst was the company\u2019s 38-to-1 stock split, announced on June 2 and distributed on June 13. Following the split, Regencell\u2019s shares quadrupled in a single session, peaked the next day, and then plunged to a six-week low before rallying again by 122% last Thursday.<\/p>\n\n\n\n<p>Despite this frenzy, Regencell\u2019s financial fundamentals remain underwhelming. According to its most recent filing in October, the company has posted losses for three consecutive years, and there have been no significant operational updates since the split.<\/p>\n\n\n\n<p>Still, the stock has surged an eye-popping 17,000% year-to-date, raising questions about what&#8217;s truly driving investor enthusiasm. Analysts note that such extreme volatility\u2014particularly in the absence of strong earnings or new developments\u2014often invites speculative trading and short squeezes.<\/p>\n\n\n\n<p>While Regencell\u2019s therapies remain in niche demand, the company&#8217;s future outlook remains unclear. For now, the stock&#8217;s erratic movement serves as a stark reminder of the risks and unpredictability tied to momentum-fueled rallies.<\/p>\n\n\n\n<p>You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2025\/07\/03\/crowdstrike-hits-record-high-after-wedbush-declares-it-cybersecuritys-gold-standard\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">CrowdStrike Hits Record High After Wedbush Declares It Cybersecurity\u2019s \u201cGold Standard\u201d<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Following a 38-to-1 stock split and explosive rally, the biotech firm&#8217;s volatile trading persists despite a multi-year loss streak Regencell Bioscience Holdings (RGC) continued its dramatic stock market saga on Monday, with shares swinging wildly throughout the trading session. After opening higher, the stock quickly turned lower, oscillating between gains and losses before settling down [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":5518,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[308,360],"tags":[421,416,418,751,417],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7490"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=7490"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7490\/revisions"}],"predecessor-version":[{"id":7492,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7490\/revisions\/7492"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/5518"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=7490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=7490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=7490"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=7490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}